Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, Gansu Province, China.
Department of Hematology and Oncology, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
Ann Hematol. 2023 Jul;102(7):1739-1744. doi: 10.1007/s00277-023-05261-y. Epub 2023 May 9.
Acute leukemia (AL) is a malignancy from hematologic stem cells (HSC). Consolidation with intensive chemotherapy is required after induced remission and repeatedly causes treatment-related bleeding that is usually attributed to chemotherapy-induced thrombocytopenia (CIT). However, our previous study demonstrated that severe deficiency of plasma coagulation factor XIII (pFXIII) also participated in the bleeding of CIT in AL. However, the relationship between pFXIII deficiency and consolidation chemotherapy was unknown. Here, we observed the concentration of pFXIII in patients with AL before and after consolidation chemotherapy and reevaluated the correlation to bleeding in myelosuppression. Thus, we found that the concentration of pFXIII before chemotherapy in all patients was markedly lower than in the control data and was further decreased by chemotherapy, related to bleeding in myelosuppression. These findings indicated that chemotherapy-induced pFXIII deficiency should be of concern and explored in depth.
急性白血病 (AL) 是一种源于造血干细胞 (HSC) 的恶性肿瘤。在诱导缓解后需要进行强化化疗巩固，这会导致与治疗相关的出血，通常归因于化疗引起的血小板减少症 (CIT)。然而，我们之前的研究表明，血浆凝血因子 XIII (pFXIII) 的严重缺乏也参与了 AL 中 CIT 的出血。然而，pFXIII 缺乏与巩固化疗之间的关系尚不清楚。在这里，我们观察了接受巩固化疗前后 AL 患者的 pFXIII 浓度，并重新评估了其与骨髓抑制性出血的相关性。因此，我们发现所有患者化疗前的 pFXIII 浓度明显低于对照数据，且化疗后进一步降低，与骨髓抑制性出血相关。这些发现表明，化疗诱导的 pFXIII 缺乏应该引起关注并深入研究。
